Enhance your nephrology practice with CME and tools focused on kidney medicine.
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Translating Evidence Into Practice: Patient-Centered, Guideline-Driven Care in ANCA-Associated Vasculitis
June 04, 2026
Glasgow
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
Improving Sleep and Mental Health in Patients with CKD-aP
Leonie Kraft, MD
Lucio Manenti, MD, PhD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD
Quantifying CKD-aP: Tools for Better Care
Advancing Patient-Centered, Guideline-Driven Management of Hyperkalemia in Adults With CKD and Associated Comorbidities
CKD-aP: Beyond the Surface
Kappa-Opioid Settings: Real-World Evidence Insights
Elevating CKD-aP Care: New Frontier
CKD-aP Treatment Tool Kit
CKD-aP or Something Else? Decoding the Diagnosis
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Patrick Rossignol, MD, PhD
Potassium Binders in Practice: Clinical Trial Evidence
The Critical Interplay: CKD, HF, and HyperkaleAmia
Javed Butler, MD
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Sydney Tang, MBBS, MD
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.